GlaxoSmithKline’s (GSK) Neutral Rating Reaffirmed at JPMorgan Chase & Co.

Share on StockTwits

JPMorgan Chase & Co. reissued their neutral rating on shares of GlaxoSmithKline (NYSE:GSK) in a research report report published on Tuesday morning, BenzingaRatingsTable reports.

GSK has been the subject of a number of other research reports. Morgan Stanley reaffirmed an underweight rating on shares of GlaxoSmithKline in a report on Monday, June 17th. Zacks Investment Research downgraded GlaxoSmithKline from a buy rating to a hold rating in a research report on Thursday, April 25th. Finally, Cowen reiterated a hold rating and set a $45.00 price target on shares of GlaxoSmithKline in a research report on Monday, June 10th. One investment analyst has rated the stock with a sell rating, fourteen have assigned a hold rating and three have given a buy rating to the stock. GlaxoSmithKline has an average rating of Hold and a consensus target price of $42.66.

GSK stock opened at $40.65 on Tuesday. The company has a quick ratio of 0.48, a current ratio of 0.71 and a debt-to-equity ratio of 7.86. The stock has a market cap of $100.39 billion, a price-to-earnings ratio of 12.86, a PEG ratio of 1.97 and a beta of 0.71. GlaxoSmithKline has a twelve month low of $36.41 and a twelve month high of $42.47. The firm’s 50-day moving average is $40.90.

GlaxoSmithKline (NYSE:GSK) last posted its earnings results on Wednesday, July 24th. The pharmaceutical company reported $0.78 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.64 by $0.14. The business had revenue of $10.04 billion during the quarter, compared to analyst estimates of $9.55 billion. GlaxoSmithKline had a return on equity of 175.45% and a net margin of 13.84%. As a group, sell-side analysts expect that GlaxoSmithKline will post 2.91 EPS for the current fiscal year.

In other news, Director Plc Glaxosmithkline bought 333,333 shares of the company’s stock in a transaction that occurred on Monday, July 1st. The stock was bought at an average price of $15.00 per share, for a total transaction of $4,999,995.00. The acquisition was disclosed in a legal filing with the SEC, which is available through this hyperlink. Insiders own 10.00% of the company’s stock.

Large investors have recently added to or reduced their stakes in the stock. Comerica Securities Inc. lifted its position in GlaxoSmithKline by 2.6% during the fourth quarter. Comerica Securities Inc. now owns 12,984 shares of the pharmaceutical company’s stock worth $502,000 after purchasing an additional 326 shares during the period. Dimensional Fund Advisors LP lifted its holdings in shares of GlaxoSmithKline by 5.2% in the fourth quarter. Dimensional Fund Advisors LP now owns 1,769,859 shares of the pharmaceutical company’s stock worth $67,626,000 after acquiring an additional 88,148 shares during the last quarter. Norges Bank bought a new position in shares of GlaxoSmithKline in the fourth quarter worth about $17,275,000. Geode Capital Management LLC lifted its holdings in shares of GlaxoSmithKline by 12.9% in the fourth quarter. Geode Capital Management LLC now owns 424,397 shares of the pharmaceutical company’s stock worth $16,216,000 after acquiring an additional 48,476 shares during the last quarter. Finally, Ropes Wealth Advisors LLC lifted its holdings in shares of GlaxoSmithKline by 21.8% in the first quarter. Ropes Wealth Advisors LLC now owns 3,348 shares of the pharmaceutical company’s stock worth $140,000 after acquiring an additional 600 shares during the last quarter. Institutional investors own 11.26% of the company’s stock.

About GlaxoSmithKline

GlaxoSmithKline plc engages in the creation, discovery, development, manufacture, and marketing of vaccines, over-the-counter medicines, and health-related consumer products worldwide. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare. The company offers pharmaceutical products comprising medicines in the therapeutic areas, such as respiratory, anti-virals, central nervous system, cardiovascular and urogenital, metabolic, anti-bacterials, dermatology, rare diseases, immuno-inflammation, and HIV, as well as vaccines.

Featured Article: What can cause a stock to outperform?

Analyst Recommendations for GlaxoSmithKline (NYSE:GSK)

Receive News & Ratings for GlaxoSmithKline Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Laurel Wealth Advisors Inc. Sells 94 Shares of Kimberly Clark Corp
Laurel Wealth Advisors Inc. Sells 94 Shares of Kimberly Clark Corp
Laurel Wealth Advisors Inc. Has $1.62 Million Stock Position in Amarin Co. plc
Laurel Wealth Advisors Inc. Has $1.62 Million Stock Position in Amarin Co. plc
Laurel Wealth Advisors Inc. Purchases 5,102 Shares of Vanguard FTSE Emerging Markets ETF
Laurel Wealth Advisors Inc. Purchases 5,102 Shares of Vanguard FTSE Emerging Markets ETF
Bank Of Princeton  Downgraded by Zacks Investment Research
Bank Of Princeton Downgraded by Zacks Investment Research
Laurel Wealth Advisors Inc. Boosts Stake in Sempra Energy
Laurel Wealth Advisors Inc. Boosts Stake in Sempra Energy
Zacks Investment Research Lowers Immunic  to Sell
Zacks Investment Research Lowers Immunic to Sell


© 2006-2019 Ticker Report